drugset / Trial / NCT01365481
Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the long-term safety and tolerability profile of valsartan and valsartan-based treatments in children with hypertension, with or without chronic kidney disease.
Timeline
- Start
- 2011-08
- Primary completion
- 2015-09
- Completion
- 2015-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Valsartan | Small molecule | 80 mg | Oral |
| Subject | Valsartan | Small molecule | 160 mg | Oral |
| Subject | Valsartan | Small molecule | 320 mg | Oral |
| Background | Amlodipine | Other / unclassified | — | — |
| Background | Hydrochlorothiazide | Unknown | — | — |